Met Life Investment Management, LLC Trevi Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $16.6 Billion
- Q2 2024
A detailed history of Met Life Investment Management, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 18,881 shares of TRVI stock, worth $62,873. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,881
Previous 22,693
16.8%
Holding current value
$62,873
Previous $78,000
28.21%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
74Shares Held
54.3MCall Options Held
15.6KPut Options Held
0-
Nea Management Company, LLC Timonium, MD11.4MShares$37.9 Million3.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$24.6 Million1.3% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$16.7 Million0.44% of portfolio
-
Viking Global Investors LP4.4MShares$14.7 Million0.05% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$11.4 Million1.12% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $194M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...